Pharmaceuticals and drug discovery | Technologies
#CEITEC MU-004 RNAutriX begin with screening services, generating a proprietary dataset of RNA–small molecule interactions. Develops tools for drug design, scaffold generation, and off-target prediction. In the long term, RNAutrix will develop its own RNA-targeted therapeutics and custom HTS instrumentation, contributing unique RNA–ligand insights to accelerate the future of RNA-targeted drug discovery and development....
Research tools and/or materials | Technologies
#CEITEC MU-003 Method to increase plant resistance to abiotic stress, particularly drought and soil salinity, by upregulating DIR13 gene expression. Abiotic stresses like drought and salinity significantly impact crop yields. Climate change exacerbates these challenges, necessitating innovative solutions. This invention focuses on enhancing plant resilience through genetic means. ...
Pharmaceuticals and drug discovery
#CEITEC MU-002 A method for designing unique peptides that can selectively target and Disrupt cellular membranes of pathogens without damaging human cells. Increasing incidence of antibiotic resistance in bacteria, along with a steady decline in the Discovery of new antibiotics, presents a global health challenge. There is a need for the discovery of...
Pharmaceuticals and drug discovery
#CEITEC MU-001 The researchers from Masaryk University developed a DNA-aptamer-based inhibitor that, in contrast to FGFR TKIs, inhibits FGFR1 but not the other existing FGFR variants (FGFR2, FGFR3, and FGFR4). In contrast to the current generation of TKIs, which targets the intracellular (kinase) domain of FGFR, the aptamer targets its extracellular domain; it significantly...